

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615767US
Express Mail Label NumberMay 23, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
ATILLASOY ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/07002

FILED: 1 JULY 2003

U.S. APPLICATION NO: 10/519,041

35 USC §371 DATE: herewith

FOR: METHODS FOR THE TREATMENT OF SINUSITIS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is supplemental to the Information Disclosure Statement filed December 22, 2004. Since it is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614

Date: 5/23/05

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PD/4-32564A
APPLICATION
10/519,041
APPLICANT
ATILLASOY ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	2 256 139	12/2/92	GB			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Foss et al., "Entomophthoramyces: Therapeutic Success by Using Amphotericin B and Terbinafine", Dermatology, Vol. 193, No. 3, pp. 258-260 (1996).
AS	Villars et al., "Special Features of the Clinical Use of Oral Terbinafine in the Treatment of Fungal Diseases", British Journal of Dermatology, Vol. 126, Suppl. 39, pp. 61-69 (1992).
AT	Hay, "The Role of Chemoprophylaxis in the Prevention of Airborne Infection by Fungal Pathogens", Journal of Hospital Infection, Vol. 18, Suppl. A, pp. 460-465 (1991).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PD/4-32564A
APPLICATION
10/519,041
APPLICANT
ATILLASOY ET AL.
FILING DATE

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BA	Kan et al., "Bioassay for SF 86-327, a New Antifungal Agent", Antimicrobial Agents and Chemotherapy, Vol. 30, No. 4, pp. 628-629 (1986).
	BB	Palmer et al., "Medical Management in Functional Endoscopic Sinus Surgery Failures", Current Opinion in Otolaryngology & Head and Neck Surgery, Vol. 11, pp. 6-12 (2003).
	BC	Luna, "Agents for Treatment of Invasive Fungal Infections", Otolaryngologic Clinics of North America, Vol. 33, No. 2, pp. 277-299 (2000).
	BD	
	BE	
	BF	
	BG	
	BH	
	BI	
	BJ	
	BK	
	BL	
	BM	
	BN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.